Published on August 29, 2009 at 1:27 AM
Mylan Inc. (Nasdaq: MYL) today is pleased to announce that its subsidiary Matrix Laboratories Ltd. has been notified by the World Health Organization (WHO) Prequalification of Medicines Programme that the WHO has withdrawn its notice of concern for Matrix Unit 8, which is located in the Vizianagaram District of India, with no remaining concerns outstanding.
Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies.
Source: http://www.mylan.com
e64964e9-90b4-4331-acd0-f892c7e46d4a|0|.0
Posted in:
Tags: Allergy